Re: quick CELG Analysis
Geno587 - Nov 24, 2008 (3 posts)
I have..but google does nothing. Google = spam
Geno587 - Nov 24, 2008 (3 posts)
I have..but google does nothing. Google = spam
|
Celgene Corporation
(Public, NASDAQ:CELG) - Add to Portfolio1228406796
0
|
|
Celgene Corporation - SWOT Analysis - companiesandmarkets.com adds ... |
| PR-Inside.com (Pressemitteilung) - 3 hours ago |
1228399197
1277257697
|
|
Options Update: Merck volatility elevated into lower 2009 outlook; ... |
| BloggingStocks - 5 hours ago |
1228394518
0
|
|
CELG: To Present At NASDAQ OMX Investor Conference @ 03:00 ET ... |
| Trading Markets (press release) - 6 hours ago |
1228308063
1277163921
|
|
Celgene Corporation and Acceleron Pharma to Present ACE-011 Data ... |
| Business Wire (press release) - Dec 3, 2008 |
1228226525
1276854765
|
|
Option Skews - National City Corp, DryShips Inc, Marvell Technology... |
| Schaeffers Research - Dec 2, 2008 |
1226320200
1461170
|
|
Celgene Corporation's Celgene Cellular Therapeutics Receives FDA ... |
| Reuters Key Development - Nov 10, 2008 |
1224840900
1447303
Advertisement
Discussions
Events
| Jan 29, 2009 |
Q4 2008 Earnings Release
- 8:30AM EST
Add to calendar
|
| Dec 4, 2008 |
Nasdaq International OMX 22nd Investor Conference
Webcast
|
| Nov 19, 2008 |
Lazard Capital Markets Healthcare Conference
Webcast
|
| Nov 12, 2008 |
Credit Suisse Group Healthcare Conference
Webcast
|
| Nov 11, 2008 |
Rodman & Renshaw Annual Global Investment Conference
Webcast
|
| Nov 3, 2008 |
Oppenheimer & Co. Annual Healthcare Conference
Webcast
|
| Oct 23, 2008 | Q3 2008 Earnings Release |
| Oct 23, 2008 |
Q3 2008 Earnings Conference Call
Webcast
|
| Oct 7, 2008 |
JMP Securities LLC Healthcare Focus Conference
Webcast
|
| Sep 23, 2008 |
UBS Global Life Sciences Conference
Webcast
|
|
More events from AOL Finance »
Add CELG to my calendars |
More Resources
Officers and directors
| Sol J. Barer Ph.D. > | Chairman of the Board, Chief Executive Officer |
| Robert J. Hugin > | President, Chief Operating Officer, Director |
| David W. Gryska > | Chief Financial Officer, Senior Vice President |
| Aart Brouwer > | President, International |
| Graham Burton > | Senior Vice President - Regulatory Affairs, Pharmacovigilance and Corporate Compliance |
| Michael D. Casey > | Lead Independent Director |
| Arthur Hull Hayes Jr.M.D. > | Director |
| Gilla Kaplan Ph.D. > | Director |
| Walter L. Robb Ph.D. > | Director |
| Rodman L. Drake > | Director |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Volume delayed by 15 min. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Link to chart
Financials
(In millions of USD)| Income Statement |
Quarterly (Sep '08) |
Annual (2007) |
Annual (2006) |
|
| Total Revenue | 592.47 | 1,405.82 | 898.87 | |
| Gross Profit | 521.93 | 1,275.58 | 772.98 | |
| Operating Income | 159.58 | 425.12 | 174.69 | |
| Net Income | 136.81 | 226.43 | 68.98 | |
| Balance Sheet | ||||
| Total Current Assets | 3,024.21 | 3,084.42 | 2,311.00 | |
| Total Assets | 4,357.42 | 3,611.28 | 2,735.79 | |
| Total Current Liabilities | 449.01 | 432.93 | 239.70 | |
| Total Liabilities | 769.06 | 767.34 | 759.61 | |
| Total Equity | 3,588.36 | 2,843.94 | 1,976.18 | |
| Cash Flow | ||||
| Net Income/Starting Line | 136.81 | 226.43 | 68.98 | |
| Cash from Operating Activities | 217.74 | 477.50 | 83.56 | |
| Cash from Investing Activities | -59.61 | -990.19 | 6.78 | |
| Cash from Financing Activities | 70.24 | 287.69 | 1,221.25 | |
| Net Change in Cash | 168.45 | -221.14 | 1,316.10 |
Key Stats & Ratios
| Quarterly (Sep '08) | Annual (2007) | Annual (TTM) | ||
| Net Profit Margin | 23.09% | 16.11% | -64.13% | |
| Operating Margin | 26.93% | 30.24% | -58.41% | |
| EBITD Margin | - | 32.48% | -52.90% | |
| Return on Average Assets | 12.92% | 7.14% | -33.87% | |
| Return on Average Equity | 15.64% | 9.40% | -43.15% | |
| Employees | 1,685 | - | - | |
| More ratios from Thomson Reuters » | ||||
Summary
Celgene Corporation is an integrated biopharmaceutical company. The Company is primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory-related diseases. The Company’s lead product is REVLIMID (lenalidomide) and THALOMID. REVLIMID was approved by the United States Food and Drug Administration (FDA), the European Commission, Swiss Agency for Therapeutic Products and Australian Therapeutic Goods Administration, for treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy. THALOMID was approved by the FDA for treatment in combination with dexamethasone of patients with diagnosed multiple myeloma and is also approved for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum, an inflammatory complication of leprosy. In March 2008, Celgene Corporation completed the acquisition of Pharmion Corporation.
More from Reuters »
|
86 Morris Avenue
Summit, NJ 07901 United States - Map +1-908-6739000 (Phone) +1-732-2714184 (Fax) |
Company website: http://www.celgene.com/ News Releases, Investor Relations, Financial Information, Corporate History/Profile, Executives, Products/Services, Employment Opportunities |